Hépatite C références article

TRAITEMENT DE L’HEPATITE
CHRONIQUE VIRALE C
Références
Docteur Denis OUZAN
Part I : Comment traiter un malade atteint d’hépatite chronique C ?
Part II : Comment optimiser le traitement ?
Part III : La prise en charge des effets secondaires
REFERENCES
1. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus
infection. N Engl J Med 2002;347:975-82.
2. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon
alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
3. Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002;26(Suppl. 2):B303-20.
4. Consensus Panel. National Institutes of Health Consensus Development Conference Statement: Management
of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36:S3-20.
5. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I et al and the GEMHEP. Hepatitis C virus genotypes in
France: relationship with epidemiology, pathogenicity and response to interferon therapy. J Viral Hepat
1999;6:435-43.
6. Hadziyannis SJ, Peginterferon alfa-2a (40 kilodaltons) and Ribavirin Combination Therapy in Chronic
Hepatitis C. A Randomized Study of the Effect of Treatment Duration and Ribavirin dose. Ann Int Med (March
2004);140:346-55.
7. Bronowicki JP, Ouzan D, Asselah T et al. Efficacy and Safety of 22 weeks of maintenance therapy with 40
KD Peginterferon alpha 2a (Pegasys) alone versus Pegasys plus Ribavirin in naïve patients with chronic
hepatitis C and genotype 1. Hepatology 2003;38:187 Abstract.
8. Zeuzem S, Diago M, Gane E et al. International multicenter randomized controlled study for the treatment of
patients with chronic hepatitis C and persistently normal ALT levels with Peginterferon alpha 2a (40 KD)
(Pegasys) and Ribavirin (Copegus). Hepatology 2003;38:106 Abstract.
9. Halfon P, Bourlière M, Deydier R et al. Independent prospective multicenter validation of biochemical
markers (fibrotest actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C.
Hepatology 2003;38:68 Abstract.
10. Torriani FJ, Rockstroh J, Rodriguez-Torres M et al. A randomized, partially blinded, multinational
comparative trial of Peginterferon alfa-2a (40KD) (Pegasys) plus Ribavirin (RBV) (Copegus) vs Interferon
alfa-2a (FN) (APRICOT). J Hepatol 2004;40:92 Abstract.
11. Rosenthal E, Pol S, Carrat F et al. Etude contrôlée randomisée comparant l’Interféron alpha-2B Pégylé plus
Ribavirine versus Interféron alpha-2B plus Ribavirine dans le traitement initial de l’hépatite C chronique chez
les patients co-infectés par le VIH (ANRS HC02-RIBAVIC). La revue de médecine interne 2004;25:S55.
12. Ferenci P, Fried WM, Chaneac M. A dynamic model to predict sustained virological response to
combination Peginterferon alpha 2a (40 KD) (Pegasys) and Ribavirin (Copegus) therapy in patients with
chronic hepatitis C. Hepatology 1993;38:995 Abstract.
13. Sanchez-Tapia JM, Diago M, Escartin P et al. Sustained virological response after prolonged treatment with
Peginterferon alpha 2a (40 KD) (Pegasys) and Ribavirin (Copegus) in treatment naïve patient with chronic
hepatitis C and detectable HCV RNA after week 4 of therapy. J Hepatol 2004;40:509 Abstract.
14. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response
in genotype-1-infected patients with chronic hepatitis C. Gastroenteroly 2002;123:1061-69.
15. Ferenci P, Shiffman ML, Fried MW et al. Early prediction of response to 40 KDA Peginterferon alpha 2a
(Pegasys) plus Ribavirin (RBV) in patients with chronic hepatitis C. Hepatology 2001;34:716 Abstract.
16. Melin P. Vivre avec une hépatite virale. Réseaux Hépatites 2004;30:14-16.
PH@RE – Les Pharmaciens en réseau
17. Zickmund S, Hillis SL, Barnett MJ et al. Hepatitis C virus-infected patients report communication problems
with physicians. Hepatology 2004;39:999-1007.
18. Hassaneim T, Cooksley G, Sulkowski M. The impact of Peginterferon alpha 2a plus Ribavirin combination
therapy on health-related quality of life in chronic C hepatitis. J Hepatol 2004;40:675-80.
19. Shiva Kumar K, Russo MW, Borczuk AC et al. Significant Pulmonary Toxicity Associated With Interferon
and Ribavirin Therapy for Hepatitis C. AJG 2002;97:2432-40.
20. Cacoub P, Sbaï A, Francès C et al. Sarcoïdose au cours d’un traitement par interféron alpha pour une
hépatite chronique virale C. Gastroenterol Clin Biol 2000;24:364-66.
21.Ledinghen V, Brudieux E, Beylot-Barry M et al. Severe local cutaneous necrosis during treatment with
interferon-alpha and ribavirin for chronic hepatitis C (letter). Gastroenterol Clin Biol 1997;21:523-24.
22. Erkek E, Karaduman A, Akcan Y et al. Psoriasis Associated with HCV and Exacerbated by Interferon
Alpha: Complete Clearance with Acitretin during Interferon Alpha Treatment for Chronic Active Hepatitis.
Dermatology 2000;179:179-80.
23. Sookoian S, Neglia V, Castano G et al. High Prevalence of Cutaneous Reactions to Interferon Alfa plus
Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Virus. Arch Dermatol 1999;135:1000.
24. Jessner W, Der-Petrossian M, Christiansen L et al. Porphyria Cutanea Tarda During Interferon/Ribavirin
Therapy for Chronic Hepatitis C. Hepatology 2002;36:1301-02.
25. Zdilar D, Franco-Bronson K, Buchler N et al. Hepatitis C, Interferon alfa, and Depression. Hepatology
2000;31:1207-11.
26. Fontana RJ. Neuropsychiatric Toxicity of Antiviral Treatment in Chronic Hepatitis C. Dig Dis
2000;18:107-16.
27. Castera L, Constant A, Couzigou P et al. Manifestations psychiatriques et psycho-comportementales au
cours de l’hépatite chronique C. L’hépatite C, éditions EDK 2004.
28. Janssen HLA, Brouwer JT, Van Der Mast RC et al. Suicide associated with alfa-interferon therapy for
chronic viral hepatitis. J Hepatol 1994;21:241-3.
29. Rifflet H, Vuillemin E, Oberti F et al. Pulsions suicidaires chez les malades atteints d’hépatite chronique C
au cours et au décours du traitement par l’interféron alpha. Gastroenterol Clin Biol 1998;22:353-7.
30. Derogatis LR, Mislisaratos N. The brief symptoms inventory : an introductory report. Psychol Med
1983;13:595-605.
31. Ouzan D, Jacques D, Collomp R et al. Doit-on se préoccuper de l’impact psychologique de l’infection à
virus de l’hépatite C et de son traitement ? Une étude cas témoins. Gastroenterol Clin Biol 2003;27:A111.
32. Fontana RJ, Schwartz SM, Gebremariam A et al. Emotional Distress During Interferon-Alfa-2B and
Ribavirin Treatment of chronic Hepatitis C. Psychosomatics 2002;43:378-85.
33. Castera L, Constant A, Henry C et al. Psychiatric events during Peginterferon and Ribavirin therapy in
chronic hepatitis C (CHC): results of a prospective study in 98 patients. J Hepatology 2004;40:470 Abstract.
34. Miller AH, Musselman DL, Nemerof C. Paroxetine for the Prevention of Depression Induced by Interferon
Alfa. N Engl J Med 2001;345:375-76.
35. Kraus MR, Schafer A, Faller H et al. Paroxetine for the treatment of interferon-alfa-induced depression in
chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-99.
36. Hauser P, Khosla J, Aurora H et al. A prospective study of the incidence and open-label treatment of
interferon–induced major depressive disorders in patients with hepatitis C. Mol Psychiatry 2002;7:942-7.
37. Gleason OC, Yates WR, Isbell MD et al. An open-label trial of citalopram for major depression in patients
with hepatitis C. J Clin Psychiatry 2002;63:194-8.
38. Chang CH, Chen KY, Lai MY et al. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with
chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1623-32.
39. Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. CID 2003;37:S315-22.
40. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M et al. Rapid Suppression of Hematopoiesis by
Standard or Pegylated Interferon-α. Gastroenterology 2002;123:141-51.
41. Dieterich DT, Wasserman R, Bräu N et al. Once-Weekly Epoetin Alfa Improves Anemia and Facilitates
Maintenance of Ribavirin Dosing in Hepatitis C Virus-Infected Patients Receiving Ribavirin plus Interferon
Alfa. AJG 2003;98:2491-99.
42. Dev A, Patel K, Muir A et al. Erythropoietin for Ribavirin-Induced Anemia in Hepatitis C: More Answers
but Many more Questions. AJG 2003;98:2344-7.
43. Soza A, Everhart JE, Ghany MG et al. Neutropenia During Combination Therapy of Interferon Alfa and
Ribavirin for Chronic Hepatitis C. Hepatology 2002;36:1273-9.
Août 2004
Hépatite C - Professionnels - Références – Dr Ouzan
2/3
PH@RE – Les Pharmaciens en réseau
44. Renou C, Harafa A, Bouabdallah R et al. Severe Neutropenia and Post-Hepatitis C Cirrhosis Treatment : Is
Interferon Dose Adaptation at Once Necessary ? AJG 2002;97:1260-3.
45.Lisker-Melman M, Di Bisceglie AM, Usala SJ et al. Development of thyroid disease during therapy of
chronic viral hepatitis with interferon α. Gastroenterology 1992;102:2155-60.
46. Deutsch M, Dourakis S, Manesis EK et al. Thyroid abnormalities in chronic viral hepatitis and their
relationship to interferon α therapy. Hepatology 1997;26:206-10.
47. Carella C, Amato G, Biondi B et al. Longitudinal study of antibodies against thyroid in patients undergoing
interferon α therapy for HCV chronic hepatitis. Horm Res 1995;44:110-4.
48. Carella C, Mazziotti G, Morisco F et al. Long-Term Outcome of Interferon-α-Induced Thyroid
Autoimmunity and Prognostic Influence of Thyroid Autoantibody Pattern at the End of Treatment. JCE & M
2001;86:1925-9.
49. Eibl N, Gschwantler M, Ferenci P et al. Development of insulin-dependent diabetes mellitus in a patient
with chronic hepatitis C during therapy with interferon-α. Eur J Gastroenterol Hepatol 2001;13:295-8.
50. Recasens M, Aguilera E, Ampurdanes S et al. Abrupt onset of diabetes during interferon-alpha therapy in
patients with chronic hepatitis C. Diabetic Medicine 2001;18:764-7.
51. Gupta R, Singh S, Tang R et al. Anterior ischemic optic neuropathy caused by interferon alpha therapy. Am
J Med 2002;112:683-4.
52. Ahmed F, Chen ST, Cofrancesco S et al. Serious ophthalmologic events during pegylated interferon and
ribavirin therapy for chronic hepatitis C: observations from the Win-R Trial. Hepatology 2003;38:1196
Abstract.
53. Ouzan D, Collomp R, Mousnier A et al. Que devient le matériel usagé (aiguilles, flacons, seringues, stylos)
après injection d’interféron à domicile ? Gastroenterol Clin Biol 2000;24 :966-7.
Août 2004
Hépatite C - Professionnels - Références – Dr Ouzan
3/3